Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongping Chen

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.
Trials|November 25, 2017
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney diseaseYeoungjee Cho, Benedicte Sautenet, Gopala Rangan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Lancet (London, England)|August 28, 2016
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trialLi Zhang, Yan Huang, Shaodong Hong, et al.
Trials|November 25, 2017
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney diseaseYeoungjee Cho, Benedicte Sautenet, Gopala Rangan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyShaodong Hong, Yaxiong Zhang, Gengsheng Yu, et al.
Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.
Nature Medicine|January 14, 2022
Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Nature Medicine|August 3, 2021
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
JAMA|November 28, 2023
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical TrialHai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, et al.
Pageof 14